Epidemiology and screening policy

Gaucher Disease

Volumn , Issue , 2006, Pages 321-340

  Meikle, Peter J ^a   Fuller, Maria ^a   Hopwood, John J ^a  

^a Gastroenterology Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055497206     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420005509     Document Type: Chapter

References (98)

1. Fried, K., Gaucher’s disease among the Jews of Israel, The Bulletin of the Research Council of Israel Proceedings of the Fourth Meeting of the Israel Genetics Circle, 1958, p. 213.
2. Fried, K., Population study of chronic Gaucher’s disease, Isr J Med Sci. 9, 1396, 1973.
3. Kolodney, E.H. et al., Phenotypic manufestations of Gaucher disease: clinical features in 48 biochemically verified Type I patients and comment of Type II patients, in Gaucher Disease: a Century of Delineation and Research, Desnick, R.J., Gatt, S., and Grabowski, G.A., Eds., Alan R. Liss, New York, 1982, p. 33.
4. Grabowski, G.A. et al., Gaucher type I (Ashkenazi) disease: considerations for heterozygote detection and prenatal diagnosis, in Gaucher Disease: a Century of Delineation and Research, Desnick, R.J., Gatt, S., and Grabowski, G.A., Eds., Alan R. Liss, New York, 1982, p. 573.
5. Matoth, Y. et al., Frequency of carriers of chronic (type I) Gaucher disease in Ashkenazi Jews, Am J Med Genet. 27, 561, 1987.
6. Beutler, E. and Grabowski, G.A., Gaucher Disease, in The Metabolic & Molecular Basis of Inherited Disease, Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., Eds., McGraw-Hill, New York, 2001, Vol. III, p. 3635.
7. Beutler, E. et al., Gaucher disease: gene frequencies in the Ashkenazi Jewish population, Am J Hum Genet. 52, 85, 1993.
8. Zimran, A. et al., High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews, Am J Hum Genet. 49, 855, 1991.
9. Horowitz, M. et al., Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population, Hum Mutat. 12, 240, 1998.
10. Kannai, R. et al., The selective advantage of Gaucher’s disease: TB or not TB? Isr J Med Sci. 30, 911, 1994.
11. Slatkin, M., A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases, Am J Hum Genet. 75, 282, 2004.
12. Lacerda, L. et al., Gaucher disease: N370S glucocerebrosidase gene frequency in the Portuguese population, Clin Genet. 45, 298, 1994.
13. Pinto, R. et al., Prevalence of lysosomal storage diseases in Portugal, Eur J Hum Genet. 12, 87, 2004.
14. Meikle, P.J. et al., Prevalence of lysosomal storage disorders, JAMA. 281, 249, 1999.
15. Dionisi-Vici, C. et al., Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey, J Pediatr. 140, 321, 2002.
16. Poorthuis, B.J. et al., The frequency of lysosomal storage diseases in The Netherlands, Hum Genet. 105, 151, 1999.
17. Dahl, N. et al., Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene, Am J Hum Genet. 47, 275, 1990.
18. Dahl, N., Hillborg, P.O., and Olofsson, A., Gaucher disease (Norrbottnian type III): probable founders identified by genealogical and molecular studies, Hum Genet. 92, 513, 1993.
19. Alfonso, P. et al., Mutation prevalence among 51 unrelated Spanish patients with Gaucher disease: identification of 11 novel mutations, Blood Cells Mol Dis. 27, 882, 2001.
20. Eto, Y. and Ida, H., Clinical and molecular characteristics of Japanese Gaucher disease, Neurochem Res. 24, 207, 1999.
21. Morar, B. and Lane, A.B., The molecular characterization of Gaucher disease in South Africa, Clin Genet. 50, 78, 1996.
22. Choy, F.Y., Wong, K., and Shi, H.P., Glucocerebrosidase mutations among Chinese neuronopathic and non-neuronopathic Gaucher disease patients, Am J Med Genet. 84, 484, 1999.
23. Ida, H. et al., Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients, Blood Cells Mol Dis. 24, 73, 1998.
24. Charrow, J. et al., The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease, Arch Intern Med. 160, 2835, 2000.
25. Rider, J.A. and Rider, D.L., Batten disease: past, present, and future, Am J Med Genet, Suppl., 5, 21, 1988.
26. Ozkara, H.A. and Topcu, M., Sphingolipidoses in Turkey, Brain Dev. 26, 363, 2004.
27. Arvio, M., Autio, S., and Louhiala, P., Early clinical symptoms and incidence of aspartylglucosaminuria in Finland, Acta Paediatr. 82, 587, 1993.
28. Petersen, G.M. et al., The Tay -Sachs disease gene in North American Jewish populations: geographic variations and origin, Am J Hum Genet. 35, 1258, 1983.
29. Martiniuk, F. et al., Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease, Am J Med Genet. 79, 69, 1998.
30. Ausems, M.G. et al., Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counseling, Eur J Hum Genet. 7, 713, 1999.
31. Chace, D.H., Kalas, T.A., and Naylor, E.W., The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism, Annu Rev Genomics Hum Genet. 3, 17, 2002.
32. Meikle, P.J. et al., Diagnosis of lysosomal storage disorders: evaluation of lysosomeassociated membrane protein LAMP-1 as a diagnostic marker, Clin Chem. 43, 1325, 1997.
33. Meikle, P.J. et al., Newborn screening for lysosomal storage disorders: Clinical evaluation of a two tier strategy, Pediatrics. 114, 906, 2004.
34. Li, Y. et al., Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease, Clin Chem. 50, 638, 2004.
35. Chamoles, N.A. et al., Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards, Clin Chim Acta. 318, 133, 2002.
36. Chamoles, N.A. et al., Gaucher and Niemann-Pick diseases - enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards, Clin Chim Acta. 317, 191, 2002.
37. Chamoles, N.A. et al., Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper, Clin Chem. 47, 2098, 2001.
38. Wilson, J.M.G. and Jungner, G., Principals and practice of screening for disease, World Health Organization, Geneva, 1968.
39. Wilcken, B., Ethical issues in newborn screening and the impact of new technologies, Eur J Pediatr. 162, 14, 2003.
40. Vallance, H. and Ford, J., Carrier testing for autosomal-recessive disorders, Crit Rev Clin Lab Sci. 40, 473, 2003.
41. Kaback, M. et al., Tay-Sachs disease - carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network, JAMA. 270, 2307, 1993.
42. Kaback, M.M., Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model, Eur J Pediatr, 159 Suppl. 3, S192, 2000.
43. Neudorfer, O. et al., Late-onset Tay-Sachs disease: Phenotypic characterization and genotypic correlations in 21 affected patients, Genet Med. 7, 119, 2005.
44. Barton, N.W. et al., Replacement therapy for inherited enzyme deficiency - macrophage- targeted glucocerebrosidase for Gaucher’s disease, N Engl J Med. 324, 1464, 1991.
45. Xu, Y.H. et al., Turnover and distribution of intravenously administered mannoseterminated human acid beta-glucosidase in murine and human tissues, Pediatr Res. 39, 313, 1996.
46. Ringden, O. et al., Ten years’ experience of bone marrow transplantation for Gaucher disease, Transplantation. 59, 864, 1995.
47. Butters, T.D. et al., Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders, Philos Trans R Soc Lond B Biol Sci. 358, 927, 2003.
48. Moyses, C., Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease, Philos Trans R Soc Lond B Biol Sci. 358, 955, 2003.
49. Hong, Y.B. et al., Feasibility of gene therapy in Gaucher disease using an adenoassociated virus vector, J Hum Genet. 49, 536, 2004.
50. Gahl, W.A. et al., Cysteamine therapy for children with nephropathic cystinosis, N Engl J Med. 316, 971, 1987.
51. Hoogerbrugge, P.M. et al., Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation, Lancet. 345, 1398, 1995.
52. Hoogerbrugge, P.M. and Valerio, D., Bone marrow transplantation and gene therapy for lysosomal storage diseases, Bone Marrow Transplant, 21, Suppl. 2, S34, 1998.
53. Hopwood, J.J. et al., Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype, J Inherit Metab Dis. 16, 1024, 1993.
54. Krivit, W. et al., Wolman disease successfully treated by bone marrow transplantation, Bone Marrow Transplant. 26, 567, 2000.
55. Krivit, W., Stem cell bone marrow transplantation in patients with metabolic storage diseases, Adv Pediatr. 49, 359, 2002.
56. Beck, M., Agalsidase alfa - A preparation for enzyme replacement therapy in Anderson-Fabry disease, Expert Opin Investig Drugs. 11, 851, 2002.
57. Mehta, A., Agalsidase alfa: specific treatment for Fabry disease, Hosp Med. 63, 347, 2002.
58. Wraith, J.E. et al., Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (Laronidase), J Pediatr. 144, 581, 2004.
59. Muenzer, J. et al., Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report, Acta Paediatr, Suppl., 91, 98, 2002.
60. Harmatz, P. et al., Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), J Pediatr. 144, 574, 2004.
61. Van den Hout, J.M. et al., Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk, Pediatrics, 113, e448, 2004.
62. Cheng, S.H. and Smith, A.E., Gene therapy progress and prospects: gene therapy of lysosomal storage disorders, Gene Ther. 10, 1275, 2003.
63. Ioannou, Y.A., Enriquez, A., and Benjamin, C., Gene therapy for lysosomal storage disorders, Expert Opin Biol Ther. 3, 789, 2003.
64. Matsuda, J. et al., Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis, Proc Natl Acad Sci U.S., 100, 15912, 2003.
65. Sawkar, A.R. et al., Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease, Proc Natl Acad Sci U.S., 99, 15428, 2002.
66. Hein, L.K. et al., alpha-L-iduronidase premature stop codons and potential readthrough in mucopolysaccharidosis type I patients, J Mol Biol. 338, 453, 2004.
67. Kakkis, E. et al., Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I, Mol Genet Metab. 83, 163, 2004.
68. Hemsley, K., King, B., and Hopwood, J., Gesellschaft fur MPS e.V., in 8th Int Symp on Mucopolysaccharide and Related Dis, Mainz, Germany, 2004, p. 37.
69. Meikle, P.J., Fietz, M.J., and Hopwood, J.J., Diagnosis of lysosomal storage disorders: current techniques and future directions, Expert Rev Mol Diagn. 4, 677, 2004.
70. Umapathysivam, K., Hopwood, J.J., and Meikle, P.J., Determination of acid alphaglucosidase activity in blood spots as a diagnostic test for Pompe disease, Clin Chem. 47, 1378, 2001.
71. Fuller, M. et al., Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease, Clin Chem. 50, 1979, 2004.
72. Hein, L.K. et al., Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots, Clin Chim Acta. 353, 67, 2005.
73. MacBeath, G. and Schreiber, S.L., Printing proteins as microarrays for high-throughput function determination, Science. 289, 1760, 2000.
74. Zhu, H. et al., Analysis of yeast protein kinases using protein chips, Nat Genet. 26, 283, 2000.
75. Gerber, S.A., Turecek, F., and Gelb, M.H., Design and synthesis of substrate and internal standard conjugates for profiling enzyme activity in the Sanfilippo syndrome by affinity chromatography/electrospray ionization mass spectrometry, Bioconjug Chem. 12, 603, 2001.
76. Gerber, S.A. et al., Direct profiling of multiple enzyme activities in human cell lysates by affinity chromatography/electrospray ionization mass spectrometry: application to clinical enzymology, Anal Chem. 73, 1651, 2001.
77. Wang, D. et al., Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns, Clin Chem. 3, 3, 2005.
78. Li, Y. et al., Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening, Clin Chem. 50, 1785, 2004.
79. Crawley, A. et al., Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry, Pediatr Res. 55, 585, 2004.
80. Fuller, M., Meikle, P.J., and Hopwood, J.J., Glycosaminoglycan degradation fragments in mucopolysaccharidosis I, Glycobiology. 14, 443, 2004.
81. Fuller, M. et al., Disease-specific markers for the mucopolysaccharidoses, Pediatr Res. 56, 733, 2004.
82. Rozaklis, T. et al., Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry, Clin Chem. 48, 131, 2002.
83. Ramsay, S.L., Meikle, P.J., and Hopwood, J.J., Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry, Mol Genet Metab. 78, 193, 2003.
84. Whitfield, P.D. et al., Characterization of urinary sulfatides in metachromatic leukodystrophy using electrospray ionization-tandem mass spectrometry, Mol Genet Metab. 73, 30, 2001.
85. Whitfield, P.D. et al., Quantification of galactosylsphingosine in the twitcher mouse using electrospray ionization-tandem mass spectrometry, J Lipid Res. 42, 2092, 2001.
86. Whitfield, P.D. et al., Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity, Mol Genet Metab. 75, 46, 2002.
87. Fuller, M. et al., Prediction of neuropathology in mucopolysaccharidosis I patients, Mol Genet Metab. 84, 18, 2005.
88. Fuller, M. et al., Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes, Clin Chem. 51, 688, 2005.
89. Brooks, D.A. et al., Immunoquantification of the low abundance lysosomal enzyme N-acetylgalactosamine 4-sulphatase, J Inherit Metab Dis. 13, 108, 1990.
90. Brooks, D.A. et al., Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients, Am J Hum Genet. 48, 710, 1991.
91. Chang, M.H. et al., Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders, Clin Chem. 46, 167, 2000.
92. Hua, C.T. et al., Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders, Clin Chem. 44, 2094, 1998.
93. Karageorgos, L.E. et al., Lysosomal biogenesis in lysosomal storage disorders, Exp Cell Res. 234, 85, 1997.
94. Staba, S.L. et al., Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome, N Engl J Med. 350, 1960, 2004.
95. Suzuki, K., Glucosylceramide and related compounds in normal tissues and in Gaucher disease, Prog Clin Biol Res. 95, 219, 1982.
96. Boscaro, F. et al., Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease, Rapid Commun Mass Spectrom. 16, 1507, 2002.
97. Mills, K., Johnson, A., and Winchester, B., Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry, FEBS Lett. 515, 171, 2002.
98. Nelson, B.C. et al., Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci. 805, 127, 2004.